Clinical Trial Update: Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of Rituximab in patients with refractory or relapsed primary central nervous system lymphoma; the study was terminated and results were posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2013-08-28